Skip to content
TickerMagic

Eris Lifesciences Limited

ERISNSEHealthcare
₹1,329
-8.10 (-0.61%) · EOD 2026-11-20

Our verdict

Buy

Valuation (79/100) does the heavy lifting; momentum (44/100) is the drag.

Buy zoneHealth A
Quality 71Momentum 44Value 79Trend 77The Spark ↓

Our fair value

Undervalued by 27%
₹1,682.08up 26.57%
Price ₹1,329Range ₹665 – ₹1,877

Buy-below (20% margin of safety): ₹1,345.67

The bottom line

Eris Lifesciences Limited earns a Buy from TickerMagic, with a blended score of 69/100. On 32.4x trailing earnings it sits cheaper than the Healthcare median of about 37.4x. The price is about 21% below its 52-week high of ₹1,692.22 and 21% above the low of ₹1,095.5. Financial health scores 85/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 5/9. The average analyst target of ₹1,696.6 implies about 28% upside across 10 analysts. It clears 7 of 13 investability checks, with durability 71, valuation 63 and momentum 44 on our 0–100 scales.

Analysis by Ankit Sharma · TickerMagic's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.

Intrinsic value
Our fair value
₹1,682.08up 26.57%
Undervalued by 27%
Price ₹1,329Range ₹664.5–₹1,877.44
DCF + relative blendhigh confidence

With a 20% margin of safety, our buy-below price is ₹1,345.67.

Analyst views

10 analysts9 buy · 1 hold · 0 sell
12-month consensus target₹1,696.6up 27.66%

1-year price

EOD · 2026-11-20
1D
down 0.61%
1W
up 4.01%
1M
up 18.62%
3M
down 1.56%
6M
down 0.01%
1Y
—

52-week range

-21.46% from the 52-week high.

Trend check
Above 50-DMA₹1,230Below 200-DMA₹1,337

Price above both moving averages reads as an intact uptrend; below both, the trend is against you.

Verdict pillars

Buy69
A
Financial health 85/100
Altman Z 4.38 · Safe zone

Piotroski F-score 5/9 — quality of earnings & balance sheet.

Our scores

Durability71
Valuation63
Momentum44

Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.

Investability checklist

Passed 7 of 13 checks
Each check screens one fundamentals, valuation or trend signal.
  • Pass: ROE above 15%: 18.1%
  • Fail: Low debt (D/E < 0.5): 0.61x
  • Fail: Positive free cash flow
  • Fail: Revenue growth > 10%: 7%
  • Pass: Earnings growing: 200%
  • Pass: Net margin ≥ 10%: 19.9%
  • Fail: Current ratio > 1.5: 0.74
  • Pass: Below our fair value
  • Pass: Margin of safety ≥ 20%
  • Fail: Above 200-day average
  • Pass: Above 50-day average
  • No data: Positive 1-year return
  • Pass: Altman Z in safe zone: Z 4.38
  • Fail: Piotroski ≥ 7: 5/9

Quarterly results

Revenue · 1Q2026
₹757 Cr
Net profit
₹282 Cr
Margin
37%
2Q2025
3Q2025
4Q2025
1Q2026
Revenue Net profitLatest revenue QoQ -6%

Annual financials

Revenue · 2026
₹3,129 Cr
Net profit
₹637 Cr
Margin
20%
2023
2024
2025
2026
Revenue Net profitLatest revenue YoY +8%

Shareholding

  • Promoter69.7%
  • Institutions22.7%
  • Public & other7.6%

Promoter holding via insider stake; institutional via reported holdings.

Key fundamentals

Market cap
₹20,320 Cr
P/E ratio
32.4
P/B ratio
5.14
EPS (TTM)
₹45.29
ROE
18.1%
Debt / Equity
0.61x
Profit margin
19.9%
Free cash flow
₹-30 Cr
52-week high
₹1,692.22
-21.46% from high
52-week low
₹1,095.5
Dividend yield
1.0%
Beta
-0.11
SWOT snapshot

Bull case vs bear case

Bull case

Strengths

  • Strong return on equity (18.1%).
  • Healthy profit margin (19.9%).
  • Financially solid — Altman Z 4.38.

Opportunities

  • Earnings growing (200% YoY).
  • Trading in our value buy zone versus sector peers.
  • Trades ~27% below our estimated fair value.

Bear case

Weaknesses

  • Price below its 200-day moving average (downtrend).

About Eris Lifesciences Limited

Eris Lifesciences Limited manufactures and distributes branded pharmaceutical formulations across multiple therapeutic areas, including antidiabetes, cardiovascular, dermatology, neuroscience, gynecology, nephrology, and oncology treatments. The company operates in India and internationally, offering products in nutrition, central nervous system care, women's health, and vitamins/minerals/nutrients, along with patient care services.

Eris Lifesciences Limited — frequently asked questions

Is Eris Lifesciences Limited a buy, hold or sell?

TickerMagic currently rates Eris Lifesciences Limited (ERIS) a Buy, based on a blended score of 69/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.

What is Eris Lifesciences Limited's fair value?

Our blended DCF and relative-valuation model estimates Eris Lifesciences Limited's fair value at about ₹1,682.08, versus a current price of ₹1,329 — roughly 27% upside. On that basis the stock looks undervalued by 27%.

Is Eris Lifesciences Limited financially healthy?

Eris Lifesciences Limited scores 85/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 5/9.

How has Eris Lifesciences Limited's share price performed?

Eris Lifesciences Limited is down 2% over three months, and last traded at ₹1,329. Past performance doesn't predict future returns.

Our verdict, fair value, financial-health and checklist are TickerMagic's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.